Skip to main content

María José Buzón Gómez

I am a researcher with extensive training in virology and immunology and a strong interest in translational research. I am dedicated to the study of new therapies aimed at curing HIV, with special emphasis on the characterization, both in blood and in different tissues, of new cellular reservoirs of HIV and the development of strategies that enhance the immune system. Recently part of my research has been directed to the study of SARS-CoV-2.

Institutions of which they are part

Head of group
Infectious Diseases
Vall Hebron Institut de Recerca

María José Buzón Gómez

Institutions of which they are part

Head of group
Infectious Diseases
Vall Hebron Institut de Recerca

I am a researcher with extensive training in virology and immunology and a strong interest in translational research. I am dedicated to the study of new therapies aimed at curing HIV, with special emphasis on the characterization, both in blood and in different tissues, of new cellular reservoirs of HIV and the development of strategies that enhance the immune system. Recently part of my research has been directed to the study of SARS-CoV-2.

Since 2015, I am the head of the HIV Translational Research Laboratory, located at the Vall d'Hebron Research Institute (VHIR), which belongs to the Infectious Diseases Department. I obtained my PhD in 2010 at AIDS Research Institute, Irsicaixa in Barcelona, and completed my postdoctoral training at the Ragon Institute of MGH, MIT and Harvard in Boston, where I was promoted to Instructor in Medicine at Harvard Medical School in 2014. My scientific interest has focused on the study of the HIV reservoirs that persist despite antiretroviral therapy (ART). I provided the first evidence that new rounds of cryptic viral replication were happening in the presence of ART (Nat Med 2010), and identified reservoir cells with stem-cell-like properties contributing to HIV long-term persistence (Nat Med 2014). My investigations are now focused on the characterization of new cellular reservoirs, the identification of novel latency reversal agents, and the design of new immune-targeted approximations aimed at depleting the latent reservoir. Recently, my lab has identified the new marker CD20 as a potential target for the transcriptionally active HIV reservoir (Nat Com 2019), has characterized the fraction of virus that can be awakened with current latency reversal agents in different populations (Plos Path 2019), and has developed new nanotechnological strategies for the elimination of the viral reservoir (NanoToday 2021). Besides, I am also a member of several evaluation panels (MINECO and AES grant calls), act as an abstract reviewer for several congresses (CROI, IAS and GESIDA), and participate in different scientific committees and international collaborative networks (BEAT-HIV Delaney Collaboratory Group). I have also contributed to innovation with 3 research patents. Importantly, I have been a recipient of several awards, including the CFAR Young Investigator Award (Harvard University Center for AIDS Research), the MGH ECOR Tosteson Award and the “International Raising Talents 2016” from the L'Oreal-Unesco Foundation For Women in Science.
A complete list of publications can be found here https://www.ncbi.nlm.nih.gov/myncbi/1TwfYvrCsLtkW/bibliography/public/

Projects

Desarrollo de una nueva estrategia terapéutica inmune-específica para la erradicación del VIH

IP: María José Buzón Gómez
Collaborators: Manuel Crespo Casal, Estrella Caballero Requero
Funding agency: Ministerio Economía, Industria y Competitividad
Funding: 181500
Reference: SAF2015-67334-R
Duration: 01/01/2016 - 31/12/2018

Identificación de reactivadores de latencia viral que actúen en células linfocitarias T CD4+ de larga vida como terapia para curar la infección por el VIH.

IP: María José Buzón Gómez
Collaborators: -
Funding agency: L'Oréal España
Funding: 15000
Reference: 2015/LOREAL/BUZON
Duration: 01/01/2016 - 31/12/2016

Red de SIDA-RIS

IP: Esteve Ribera Pascuet
Collaborators: Adria Curran Fàbregas, Vicenç Falcó Ferrer, Manuel Crespo Casal, Inmaculada Ocaña Rivera, Estrella Caballero Requero, Pere Soler Palacín, Maria Espiau Guarner, María José Buzón Gómez, Jordi Navarro Mercadé, Joaquin Burgos Cibrian, Judit Grau Exposito, Andrea Martín Nalda, Marie Antoinette Frick
Funding agency: Instituto de Salud Carlos III
Funding: 200800
Reference: RD12/0017/0003
Duration: 01/01/2013 - 30/09/2017

Related news

The new protocol has the same efficacy as the standard one, but only a quarter of the duration, reducing dropout rates and side effects.

The initiative, carried out at the Consulate of Bolivia, has resulted in 307 new tests for the diagnosis of Chagas disease

The study shows that blocking the KLRG1 receptor helps to recover the activity of the natural killer cells of the immune system and reactivate the virus reservoir to fight infection.

Related professionals

Vanesa Dávalos Yerovi

Vanesa Dávalos Yerovi

Predoctoral researcher
Research Group of Physical Medicine and Rehabilitation
Read more
Joan Daniel Vargas Figueroa

Joan Daniel Vargas Figueroa

Research assistant
Stroke research
Read more
Marc Patricio Liebana

Marc Patricio Liebana

Predoctoral researcher
Nephrology and kidney transplantation
Read more
Monica Kruger

Monica Kruger

Research technician
Pneumology
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.